Cardiac Marker
Cardiac Marker Market by Product (Instruments, Reagents & Kits), Biomarker Type (BNP Or NT-ProBNP, CK-MB, Hs-CRP), End-User, Indication - Global Forecast 2024-2030
360iResearch Analyst
Want to know more about the cardiac marker market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[189 Pages Report] The Cardiac Marker Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.16 billion in 2024, at a CAGR 9.71% to reach USD 7.29 billion by 2030.

Cardiac markers are substances or molecules measured in the blood to diagnose and monitor various cardiac conditions, particularly those related to heart muscle damage or stress. These markers are often used in clinical settings, such as hospitals and laboratories, to assist in diagnosing, prognosis, and monitoring cardiovascular diseases. They are particularly widely used in the diagnosis of conditions such as myocardial infarction and other forms of acute coronary syndrome. With an increased emphasis on accurate and early diagnosis in cases of cardiovascular diseases (CVD), the cardiac markers market's valuation has been progressively escalating. The rising incidence of cardiovascular conditions and the growing global geriatric population fuel the market demand for cardiac markers. Rising demand for point-of-care testing and the steady development in healthcare infrastructure, including well-equipped labs and trained personnel, globally aids the industry's growth. However, High prices associated with cardiovascular procedures and solutions affect market adoption. The evolution of the biomedical industry, particularly diagnostic technologies, and government healthcare initiatives and programs aiming to foster preventative care are instrumental in escalating the demand for cardiac markers and creating a significant growth opportunity for the market.

Regional Insights

The Americas has a significant market landscape in the cardiac marker market due to a high prevalence of cardiovascular diseases, well-established healthcare facilities, and major market players. The increasing incidence of heart attacks and the strong focus on early diagnosis and treatment are driving the demand for cardiac marker tests in this region. Moreover, advancements in the biotechnology sector and higher adoption rates for novel diagnostics methodologies contribute to America's cardiac marker market growth. Europe's market growth in the cardiac marker is propelled by the rising aging population, which is more prone to chronic diseases, including coronary heart disease. The availability of cutting-edge healthcare facilities, rising healthcare expenditures, and favorable regulatory policies also support the growth of the European cardiac marker market. Moreover, several key market players and ongoing research activities in the cardiac biomarkers space further stimulate market growth. The Asia-Pacific region is projected to show a significant cardiac marker market growth rate during the forecast period attributed to the large population base, the rising incidences of lifestyle diseases, and the gradual improvement in healthcare infrastructure across emerging economies.

Cardiac Marker Market
To learn more about this report, request a free PDF copy
Market Dynamics

The market dynamics represent an ever-changing landscape of the Cardiac Marker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Increasing occurrence of cardiovascular diseases
    • Accessibility to a large variety of reagents and kits for cardiac biomarkers
    • Improved healthcare infrastructure and spending across economies
  • Market Restraints
    • High prices associated with cardiovascular procedures and solutions
  • Market Opportunities
    • Ongoing advancements in cardiac markers
    • Persistent improvement in the essence of point-of-care diagnostic solution
  • Market Challenges
    • Stringent regulations and approvals for cardiac markers
Market Segmentation Analysis
  • Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins

    Chemiluminescence immunoassay (CLIA) systems are sophisticated diagnostic instruments that detect high-sensitivity cardiac markers such as troponin, CK-MB, and myoglobin. These instruments utilize luminogenic substrates that emit light upon reaction with specific enzymes in the presence of the targeted antigen. Enzyme-linked immunosorbent assay (ELISA) kits and instruments are vital in detecting and quantifying cardiac markers. These assays rely on an enzyme-conjugate reaction that produces a measurable colorimetric change. ELISA systems offer flexibility in terms of scalability and are known for their specificity and high sensitivity. Immunochromatography is a rapid and simple diagnostic technique that utilizes the movement of particles along a membrane via capillary action. It involves using antibodies and antigens to detect specific biomarkers, such as cardiac markers. Immunofluorescence is a technique that uses fluorescent dyes or markers to detect the presence of specific antibodies or antigens, and it is employed for more detailed and specific analysis in the context of cardiac markers. Reagents and kits for cardiac marker detection comprise a wide range of immunoassays optimized for various analytical platforms. These consumables often include antibodies, antigens, buffers, and substrates specifically engineered for the qualitative and quantitative assessment of cardiac-specific proteins.

  • Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure

    BNP and NT-proBNP are biomarkers for diagnosing and managing heart failure. BNP is discharged by ventricular myocytes in reaction to increased wall tension, typically due to fluid overload in heart failure. When found at low levels, these peptides have a strong negative predictive value for cardiac risk and heart failure. In contrast, elevated levels are indicative of an increased risk of adverse cardiovascular events. Creatine Kinase-MB (CK-MB) is an isoenzyme of creatine kinase (CK) and is one of the traditional biomarkers for diagnosing myocardial infarction (MI). It is found mainly in cardiac cells and increases in the blood following the death of heart muscle cells. High-sensitivity C-Reactive Protein (Hs-CRP) is an acute-phase protein and a non-specific inflammatory biomarker that can indicate systemic inflammation. It is often used to assess the risk of cardiac disease and other cardiac risk factors. Myoglobin is an early but non-specific marker of myocardial injury. It is most valuable when used alongside more specific cardiac markers, such as troponins, for the early assessment of myocardial infarction. Troponin I and T are regulatory proteins that are part of the cardiac muscle contractile apparatus and are highly specific and sensitive biomarkers for myocardial injury.

  • End-User: Significant utilization of cardiac marker in laboratory testing facilities

    Laboratory testing facilities are typically equipped with sophisticated equipment and skilled personnel capable of performing a comprehensive range of tests. Hospitals and independent diagnostic labs are the primary constituents of this sector. They offer accurate and high-volume cardiac marker testing services, integral for diagnosing various cardiovascular conditions, including myocardial infarctions (heart attacks) and acute coronary syndromes. Point of Care (POC) testing facilities include emergency departments, ambulances, clinics, and physician offices. The immediacy of results allows for swift clinical decision-making, critical in managing cardiac emergencies. POC testing for cardiac markers, such as troponin, BNP (B-type natriuretic peptide), and D-dimer, has revolutionized diagnosing and managing cardiovascular diseases. POCT systems for cardiac markers are designed for simplicity and speed, reducing the turnaround time for decision-making in acute care settings.

  • Indication: Potential adoption of cardiac markers in congestive heart failure situations

    In congestive heart failure (CHF) situations, cardiac markers are crucial in diagnosis, prognosis, and management. B-type natriuretic peptide (BNP) and N-terminal-pro BNP (NT-proBNP) are the primary biomarkers used to confirm suspected CHF, differentiate it from other causes of dyspnea, and assess the severity of the condition. Elevated levels of BNP or NT-proBNP are associated with heart failure, and these markers are used for both diagnosis and monitoring of CHF patients. In myocardial infarction (MI), Troponin I, Troponin T, and creatine kinase-MB (CK-MB) are commonly used cardiac markers for myocardial infarction. Troponins are sensitive and specific markers for detecting myocardial injury. Elevated levels of troponins indicate myocardial infarction and help in diagnosing acute coronary syndrome.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cardiac Marker Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cardiac Marker Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cardiac Marker Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Cardiac Marker Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Cardiac Marker Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cardiac Marker Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cardiac Marker Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cardiac Marker Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Cardiac Marker Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Cardiac Marker Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Marker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Marker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays

    Mindray has expanded its cardiac biomarker portfolio with the introduction of new assays. These assays include troponin T, high-sensitive troponin I (hsTnI), and N-terminal pro-B type natriuretic peptide (NT-proBNP). These markers are crucial for the early diagnosis and risk stratification of various cardiovascular diseases, such as acute coronary syndrome, heart failure, sepsis, and stroke. [Published On: 2023-10-23]

  • AUDIT MicroControls, Inc. Announces Linearity FLQ Cardiac Markers for Roche Systems

    AUDIT MicroControls, Inc. partnerwed with Roche Systems of Cardiac Markers to exhibit linearity across the entire measurement range, ensuring accurate and reliable results. These systems demonstrate robust performance even in samples with complex and heterogeneous compositions. [Published On: 2023-06-29]

  • Cipla Launches Diagnostic Device For Multiple Health Conditions

    Cipla has introduced a diagnostic device that detects various health conditions, including cardiac markers such as Troponin I and Myoglobin. This point-of-care testing device delivers reliable results quickly, making it invaluable for doctors and healthcare professionals to identify a wide range of diseases, from cardiac to infectious. [Published On: 2023-01-18]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Marker Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Marker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aehealth Limited, Becton, Dickinson and Company, BG Medicine Inc., Bio-Rad Laboratories, Inc., Biomérieux SA, Danaher Corporation, DiaSorin S.P.A., HyTest Ltd., LSI Medience Corporation, PerkinElmer Inc., QuidelOrtho Corporation, Randox Laboratories Ltd., Roche Diagnostics Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.

Cardiac Marker Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Cardiac Marker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Instruments
      • Chemiluminescence
      • ELISA
      • Immunochromatography
      • Immunofluorescence
    • Reagents & Kits
  • Biomarker Type
    • BNP Or NT-ProBNP
    • CK-MB
    • Hs-CRP
    • Myoglobin
    • Troponin I & T
  • End-User
    • Laboratory Testing Facilities
    • Point of Care Testing Facilities
  • Indication
    • Congestive Heart Failure
    • Myocardial Infarction

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Cardiac Marker Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Cardiac Marker Market, by Product
  7. Cardiac Marker Market, by Biomarker Type
  8. Cardiac Marker Market, by End-User
  9. Cardiac Marker Market, by Indication
  10. Americas Cardiac Marker Market
  11. Asia-Pacific Cardiac Marker Market
  12. Europe, Middle East & Africa Cardiac Marker Market
  13. Competitive Landscape
  14. Competitive Portfolio
  15. List of Figures [Total: 24]
  16. List of Tables [Total: 466]
  17. List of Companies Mentioned [Total: 17]
The Future of Cardiac Marker Testing: Rapid and Accurate Diagnostics at Point-of-Care
December 28, 2023
The Future of Cardiac Marker Testing: Rapid and Accurate Diagnostics at Point-of-Care
In recent years, advancements in healthcare technology have paved the way for faster and more accurate diagnosis of medical conditions, especially cardiovascular disease (CVD). Cardiac marker testing, which detects the presence of certain proteins or enzymes in the blood, is a crucial part of diagnosing CVD. With the persistent improvement in the essence of point-of-care diagnostic solutions, diagnostic accuracy is not the only goal, as these tests should be faster and more efficient. This blog post explores the scope of cardiac marker testing and how it is improving healthcare outcomes.

Understanding Cardiac Marker Testing:

Cardiac markers are indicators of heart damage or stress that can be found in the blood. They are used to diagnose a variety of cardiovascular diseases, including myocardial infarction (MI), heart failure, and angina. The most commonly used cardiac markers are troponin, creatine kinase (CK), and brain natriuretic peptide (BNP). Traditionally, patients have to wait hours for laboratory results. Point-of-care diagnostic solutions are game-changers as they provide rapid and accurate diagnostic results at the point-of-care (POC).

Importance of Point-of-Care Testing:

POC testing refers to diagnostic testing that is conducted outside of a laboratory, typically close to the patient. The benefits of POC testing are numerous, including faster diagnosis, reduced healthcare costs, and improved patient outcomes. Cardiac marker POC testing has been particularly valuable in emergency medicine, as it allows physicians to quickly assess patients who have been brought to the emergency room with chest pain or similar symptoms of a heart attack.

Technological Advances in Cardiac Marker Testing:

In recent years, significant technological advancements have spurred the development of more accurate and efficient cardiac marker POC tests. One such example is the development of highly sensitive troponin assays, which can detect very low levels of troponin in the blood and can diagnose MI earlier than traditional tests. Another example is the use of biochip technology that incorporates multiple biomarkers, which improves the diagnostic accuracy of CVDs.

Role of Artificial Intelligence (AI) in Cardiac Marker Testing:

With the rise of AI in healthcare, it is predicted that the integration of AI in cardiac marker testing will bring further advancements in POC diagnostics. AI algorithms could help detect patterns and relationships in large-scale data sets derived from POC testing. As a result, AI algorithms could provide faster decision-making support to healthcare providers. AI is poised to help shift the focus of healthcare from treatment to prevention.

Future of Cardiac Marker Testing:

With the steady progression of technological advancements, future improvements in cardiac marker POC testing are expected to increase efficiency and reduce the time to diagnose CVDs. The ultimate goal is to develop a cardiac marker that can predict the onset of CVDs before any symptoms appear to take preventive measures. These may include changes in lifestyle, such as exercise and diet, or early-stage medical interventions.

Cardiac marker testing is a critical part of the diagnosis of Cardiovascular disease. The persistent advancement in the essence of point-of-care diagnostic solutions is revolutionizing the way cardiac markers are tested. Rapid and accurate POC diagnostic solutions are the future of cardiac marker testing, assuming an essential part in early diagnosis and improved clinical outcomes. The future looks promising, and advancing technologies such as AI are paving the way for the next generation of point-of-care diagnostics.

Frequently Asked Questions
  1. How big is the Cardiac Marker Market?
    Ans. The Global Cardiac Marker Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.16 billion in 2024.
  2. What is the Cardiac Marker Market growth?
    Ans. The Global Cardiac Marker Market to grow USD 7.29 billion by 2030, at a CAGR of 9.71%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.